2013
Resultado da Busca
Anne E. Wojcicki (/ wuːˈtʃɪtski / woo-CHITS-kee; [2] born July 28, 1973) is an American entrepreneur who co-founded and is CEO of the personal genomics company 23andMe. She founded the company in 2006 with Linda Avey and Paul Cusenza. She is a co-founder and board member of the Breakthrough Prize.
Há 1 dia · Due to that difference—and the fact that Wojcicki controls 49% of 23andMe votes—they resigned. Wojcicki is now the only board member left. In an internal memo Wojcicki circulated shortly after ...
Há 2 dias · Anne Wojcicki, co-founder and chief executive officer of 23andme Inc., during the South by Southwest (SXSW) festival in Austin, Texas, US, on Friday, March 10, 2023. All seven independent ...
Há 2 dias · Save. 23andMe Holding Co.co-founder and Chief Executive Officer Anne Wojcickitold employees that she remains committed to taking the genetic testing company private following the resignation of ...
Há 2 dias · All seven independent directors of DNA-testing company 23andMe ME -0.29% resigned Tuesday, following a protracted negotiation with founder and Chief Executive Anne Wojcicki over her plan to take ...
1 de jun. de 2023 · Anne Wojcicki is the cofounder and CEO of 23andMe, a pioneering direct-to-consumer genetics testing firm based in South San Francisco, California. In June 2021, 23andMe went public in...
20 de mai. de 2021 · May 20, 2021. Anne Wojcicki, CEO of 23andMe, spent a decade in healthcare and biotechnology before launching the DNA testing and analysis company in 2006. Her goal was twofold: to help...
10 de abr. de 2020 · Anne Wojcicki: ‘This is the way the world is going’. As chief executive of 23andMe, she holds the key to a vast genetic database. What will she do with it? Hannah Kuchler. April 10 2020. Stay...
25 de abr. de 2023 · Genetics have the potential to transform how we predict, prevent, and treat almost all human disease, writes 23andMe CEO Anne Wojcicki.
5 de mai. de 2022 · In this exclusive interview, CNBC’s Julia Boorstin sits down with co-founder Anne Wojcicki who reflects on the biotech disruptor’s successes and failures, while also weighing in on the trends...
